Urovant Sciences (NASDAQ:UROV) Downgraded by Zacks Investment Research

Zacks Investment Research cut shares of Urovant Sciences (NASDAQ:UROV) from a hold rating to a sell rating in a report released on Wednesday, Zacks.com reports.

According to Zacks, “Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing therapies for urologic conditions. The company’s product candidate pipeline consists of vibegron, an oral, once-daily, small molecule beta-3 agonist being evaluated in an international pivotal Phase 3 clinical trial for the treatment of overactive bladder. hMaxi-K, is a novel gene therapy being developed for patients with overactive bladder who have failed oral pharmacological therapy. Urovant Sciences Ltd. is based in Floor London, United Kingdom. “

Several other analysts have also commented on the company. HC Wainwright set a $28.00 price objective on Urovant Sciences and gave the company a buy rating in a report on Monday, October 21st. ValuEngine lowered Urovant Sciences from a buy rating to a hold rating in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. Urovant Sciences has an average rating of Hold and a consensus target price of $21.44.

Shares of UROV opened at $9.62 on Wednesday. The company has a current ratio of 6.20, a quick ratio of 6.20 and a debt-to-equity ratio of 0.29. Urovant Sciences has a 12 month low of $4.05 and a 12 month high of $14.49. The stock’s 50 day moving average is $9.64 and its two-hundred day moving average is $8.57. The firm has a market cap of $293.09 million, a P/E ratio of -2.17 and a beta of 1.66.

Urovant Sciences (NASDAQ:UROV) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($1.15) by $0.30. Equities research analysts forecast that Urovant Sciences will post -4.02 EPS for the current year.

Several large investors have recently modified their holdings of UROV. Perceptive Advisors LLC boosted its stake in shares of Urovant Sciences by 116.7% in the second quarter. Perceptive Advisors LLC now owns 1,875,426 shares of the company’s stock worth $14,835,000 after acquiring an additional 1,010,067 shares during the last quarter. FMR LLC boosted its stake in shares of Urovant Sciences by 28.4% in the first quarter. FMR LLC now owns 1,710,836 shares of the company’s stock worth $17,194,000 after acquiring an additional 378,135 shares during the last quarter. Atria Investments LLC acquired a new stake in shares of Urovant Sciences in the second quarter worth approximately $3,420,000. LVW Advisors LLC acquired a new stake in shares of Urovant Sciences in the third quarter worth approximately $372,000. Finally, Marshall Wace LLP acquired a new stake in shares of Urovant Sciences in the first quarter worth approximately $325,000. 24.23% of the stock is currently owned by hedge funds and other institutional investors.

Urovant Sciences Company Profile

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.

Further Reading: How to Profit and Limit Losses With Stop Orders

Get a free copy of the Zacks research report on Urovant Sciences (UROV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.